Vaginal dryness, normal hormones, yet nothing has helped. Here's the biological reason.

Estrogen doesn’t work by simply existing in your bloodstream. It only affects your body when it binds to estrogen receptors, which sit on the surface of cells throughout your reproductive tract, brain, blood vessels, and skin. The ESR1 gene codes for estrogen receptor alpha, the primary receptor in vaginal and clitoral tissue. This receptor is what allows estrogen to trigger the cascade of changes that support arousal, blood flow, lubrication, and vaginal tissue thickness.

ESR1 variants, particularly the PvuII and XbaI polymorphisms, change how efficiently these receptors function. People carrying certain variants have estrogen receptors that are less sensitive to circulating estrogen, meaning their tissues respond less to the same hormone levels that would be adequate for someone else. Studies show that roughly 40% of the population carries one of these variants. The result is that your body may produce normal or even elevated estrogen on bloodwork, yet your vaginal tissue, breast tissue, and bone never receive the full signal.

You experience this as vaginal dryness and reduced arousal despite normal hormone levels. Topical estrogen creams and systemic HRT may help because they flood your system with higher estrogen concentrations, trying to overcome the receptor insensitivity. But if you have an ESR1 variant, you may need either higher doses or a different approach entirely, such as addressing the other genes in this pathway that control blood flow and dopamine.

Testosterone and estrogen are not separate hormones; they exist on a spectrum. Your ovaries make testosterone first, then convert it to estrogen via an enzyme called aromatase, coded by the CYP19A1 gene. This balance between testosterone and estrogen is critical for sexual desire, clitoral sensitivity, vaginal lubrication, and bone density. Both hormones are necessary. Too much estrogen relative to testosterone dampens sexual motivation. Too much testosterone relative to estrogen can cause acne and mood changes. The sweet spot is a healthy ratio.

CYP19A1 variants alter aromatase activity. Some variants increase aromatase activity, meaning you convert testosterone to estrogen very efficiently; others decrease it. If you carry a variant that increases aromatase, you may have a low testosterone-to-estrogen ratio, leaving you with low sexual desire despite adequate total hormone levels. This affects roughly 30-50% of women depending on ancestry. You feel neither aroused nor interested in sex. Vaginal tissue is dry because low testosterone impairs the vascular and neurological responsiveness that testosterone normally supports.

You experience this as persistent low libido, difficulty with arousal and orgasm, and vaginal dryness that doesn’t respond to estrogen alone. Adding testosterone (via cream, patch, or pellet) or using supplements that naturally modulate aromatase may help rebalance your hormone ratio and restore sexual desire and lubrication.

Your bloodwork says you have plenty of testosterone and estrogen. But here’s what standard testing doesn’t measure: how much of that hormone is actually available to your cells. The SHBG protein acts like a sponge, binding up testosterone and estrogen in your bloodstream. Only the fraction that remains unbound, called free hormone, can actually enter your cells and create an effect. High SHBG means most of your hormones are sequestered and unavailable. Low SHBG means more of your hormones are free and active.

The SHBG gene has common variants (rs6259, rs1799941) that affect how much SHBG your liver produces. People carrying certain variants have elevated SHBG, which binds and inactivates testosterone and estrogen, leaving very little free hormone available to your tissues despite normal total hormone levels on bloodwork. Roughly 30-40% of the population carries one of these variants. This is one of the most common reasons why a woman’s hormone bloodwork looks normal yet her symptoms suggest deficiency.

You experience this as persistent low libido, vaginal dryness, and reduced arousal despite normal hormone levels on testing. Your gynecologist sees the normal bloodwork and dismisses your symptoms. But your cells are starving for active hormone because it’s all bound up. Topical treatments don’t help because they can’t overcome a systemic SHBG problem. You need to either lower your SHBG or supplement with higher total hormone to increase the free fraction.

Sexual desire is not primarily an hormonal phenomenon; it’s a neurochemical one. The primary driver of sexual motivation, arousal, and pleasure is dopamine, a neurotransmitter released in the reward centers of your brain during anticipation and pleasure. Dopamine makes you want sex, makes sex feel good, and makes you seek it out again. Without adequate dopamine function, hormones alone cannot restore libido. The COMT enzyme breaks down dopamine after it’s released, determining how long dopamine stays active in your brain.

The COMT Val158Met variant, carried by roughly 25% of people in European ancestry as homozygous slow, affects dopamine clearance speed. People with the met/met (slow) variant clear dopamine slowly, so it stays active longer. People with the val/val (fast) variant clear dopamine quickly, so it’s gone fast. The relationship to libido is non-linear: both fast and slow COMT can impair sexual desire, but for opposite reasons. Fast COMT leads to low dopamine and low motivation. Slow COMT can lead to overstimulation and reduced dopamine sensitivity. This matters because it changes how you should approach dopamine support.

If you have fast COMT, you experience low sexual motivation, difficulty getting aroused, and persistent low desire despite normal hormones. You feel unmotivated and flat. If you have slow COMT, you may experience anxiety or overstimulation that interferes with arousal, or reduced pleasure during sex because your dopamine signaling is dysregulated. Either way, vaginal dryness follows because arousal and lubrication are dopamine-dependent. Standard treatments that only address hormones completely miss the dopamine piece.

Vaginal lubrication is not a passive process. When you’re aroused, arteries in the vaginal wall dilate, flooding the tissue with blood. This blood brings oxygen and triggers the vaginal epithelial cells to secrete fluid through a process called transudation. Dryness happens when blood flow is inadequate. The MTHFR gene codes for an enzyme central to methylation and to the synthesis of nitric oxide, a molecule that tells blood vessels to relax and dilate. Impaired MTHFR function reduces nitric oxide production, constricting blood vessels and impairing blood flow to sexual tissue.

The MTHFR C677T variant, carried by roughly 40% of people in European ancestry, reduces enzyme efficiency by 40-70%. This impairs your body’s ability to produce nitric oxide and maintain healthy methylation, both of which are essential for the vascular response that creates lubrication. You can have normal estrogen and testosterone, but if your blood vessels can’t dilate properly, your vaginal tissue will be dry and unresponsive. This is why Viagra and Cialis (which enhance nitric oxide signaling) sometimes help women with MTHFR variants, even though they’re not FDA-approved for female use.

You experience this as vaginal dryness that doesn’t respond to hormone replacement because the problem isn’t hormone deficiency, it’s vascular insufficiency. Your vagina doesn’t lubricate during arousal because the blood vessels aren’t dilating enough. Orgasm may be difficult or impossible because the vascular and neurological response is blunted. Standard treatments ignore the vascular component entirely.

Serotonin is often called the happiness chemical, but when it comes to sexual desire, serotonin is actually the brakes. High serotonin suppresses dopamine and sexual motivation. This is why SSRIs, the most commonly prescribed antidepressants, often cause sexual side effects as a direct pharmacological consequence, not a psychological one. The SLC6A4 gene codes for the serotonin transporter, which removes serotonin from synapses after it’s released. This determines how much serotonin accumulates in your brain.

The SLC6A4 5-HTTLPR polymorphism comes in long and short variants. People carrying the short allele have higher serotonin activity because the short form of the transporter is less efficient at clearing serotonin, allowing it to accumulate and exert stronger suppression on dopamine and sexual motivation. Roughly 40% of the population carries at least one short allele. This is intrinsic, not medication-related. Even if you’re not taking SSRIs, a short SLC6A4 allele means your brain chemistry is naturally tilted toward higher serotonin and lower dopamine, which directly suppresses sexual desire and arousal.

You experience this as persistent low libido, difficulty becoming aroused, and difficulty reaching orgasm, even though your hormones are normal and you’re in a relationship you care about. You’ve felt this way for years, possibly since adolescence. Sex feels like an obligation, not a pleasure. Vaginal dryness reflects the absence of arousal, which is driven by dopamine and opposed by serotonin. No amount of estrogen replacement will fix this because the problem is neurochemical, not hormonal.